Dose-Response Association between Alcohol Consumption and Kidney Cancer Risk Differs According to Glycemic Status: A Nationwide Cohort Study of 9.4 Million Individuals

Joo-Hyun Park; Jung Yong Hong; Kyungdo Han; Jay J. Shen; Se Hoon Park

doi:10.4143/crt.2024.996

Articles

Page Path: HOME > Cancer Res Treat > Volume 57(4); 2025 > Article

Original Article Genitourinary cancer Dose-Response Association between Alcohol Consumption and Kidney Cancer Risk Differs According to Glycemic Status: A Nationwide Cohort Study of 9.4 Million Individuals: Joo-Hyun Park^1,2, Jung Yong Hong^2,3,4, Kyungdo Han⁵, Jay J. Shen², Se Hoon Park³; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2025;57(4):1178-1186.
DOI: https://doi.org/10.4143/crt.2024.996
Published online: January 31, 2025

¹Department of Family Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea

²Department of Healthcare Administration and Policy, School of Public Health, University of Nevada Las Vegas, Las Vegas, NV, USA

³Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

⁴Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Science and Technology (SAIHST), Sungkyunkwan University, Seoul, Korea

⁵Department of Statistics and Actuarial Science, Soongsil University, Seoul, Korea

Correspondence: Jung Yong Hong, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Tel: 82-2-3410-1211 E-mail: hongjungyong@naver.com

Co-correspondence: Jay J. Shen, Department of Healthcare Administration and Policy, School of Public Health, University of Nevada Las Vegas, 4700 S. Maryland Parkway, Suite 335, Las Vegas, NV 89119, USA
Tel: 1-702-895-5830 E-mail: jay.shen@unlv.edu

• Received: October 15, 2024 • Accepted: January 30, 2025

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

4,805 Views
131 Download

prev next

Full Article

Download PDF

Abstract

Purpose
Previous studies suggested an association between alcohol consumption and reduced kidney cancer risk. Given a potential interaction between alcohol’s insulin-sensitizing effect and hyperglycemia-related insulin resistance, we aimed to assess whether the dose-response association between alcohol intake and kidney cancer risk varies based on glycemic status.
Materials and Methods
This nationwide cohort study analyzed data from 9,492,331 adults who underwent a national health screening program in 2009 and were followed until 2018. Multivariable-adjusted Cox regression models were applied to estimate the adjusted hazard ratios (HRs) and 95% confidence intervals (CIs).
Results
Over a median follow-up period of 8.3 years, 12,381 participants were diagnosed with kidney cancer. A U-shaped relationship between alcohol consumption and kidney cancer risk was observed among individuals with normoglycemia (light-to-moderate: HR, 0.94; 95% CI, 0.89 to 0.99 and heavy: HR, 1.00; 95% CI, 0.91 to 1.09, respectively). In prediabetic individuals, alcohol consumption was not significantly associated with kidney cancer risk. In individuals with diabetes, a dose-dependent increase in kidney cancer risk was noted with higher alcohol consumption (light-to-moderate consumption: HR, 1.12; 95% CI, 1.03 to 1.22; heavy consumption: HR, 1.24; 95% CI, 1.09 to 1.42; p for trend < 0.01).
Conclusion
A modest U-shaped dose-response association between alcohol consumption and kidney cancer risk was observed exclusively in individuals with normoglycemia. Individuals with diabetes demonstrated a dose-dependent increased risk of kidney cancer with higher alcohol consumption. Tailored patient education and personalized risk assessments regarding alcohol consumption and kidney cancer risk should be emphasized over a generalized ‘one-size-fits-all’ approach.
Key words: Kidney neoplasms, Alcohol drinking, Glycemic status, Risk factors

Introduction

Kidney cancer is the 14th most frequently diagnosed cancer worldwide, with over 430,000 new cases reported in 2022 [1,2]. The incidence of kidney cancer has nearly doubled over the past few decades, with an annual increase of approximately 2% [1,2]. Established risk factors for kidney cancer include hypertension, smoking, obesity, diabetes, and chronic kidney disease (CKD) [3]. Elucidating potential risk factors associated with kidney cancer is essential for reducing the rapidly growing burden of the disease.

Although alcohol is classified as a carcinogen [4], the relationship between alcohol consumption and kidney cancer risk remains inconclusive, with studies reporting either an inverse [5-11] or null [12,13] association. The inverse association between alcohol consumption and kidney cancer risk is supported by evidence suggesting that moderate alcohol intake increases insulin sensitivity, reduces inflammation, and promotes diuresis [14,15]. However, the effect of alcohol on kidney cancer risk may vary depending on glycemic status. Hyperglycemia, including diabetes and prediabetes, is associated with insulin resistance, chronic inflammation, and renal dysfunction [16,17].

Although a potential interaction between alcohol’s insulin-sensitizing effect and hyperglycemia-related insulin resistance is proposed, no study has examined whether the dose-response relationship between alcohol consumption and kidney cancer risk varies based on glycemic status. Moreover, previous cohort studies were limited by small sample sizes [8-11] and insufficient adjustment for important confounders, such as diabetes and CKD [5-11]. Previous case–control studies on alcohol consumption and kidney cancer risk were significantly limited by recall, selection, and survivorship biases [18,19].

Global alcohol consumption has been steadily increasing, with per capita consumption rising from 5.9 L in 1990 to 6.5 L in 2017, and projections indicate that it could reach 7.6 L by 2030 [20]. Additionally, diabetes and prediabetes affect more than half of adults in most developed countries [21,22]. Investigating the interaction between alcohol consumption and hyperglycemia could enable personalized risk assessment and help reduce the growing burden of kidney cancer.

Thus, we performed a large-scale, nationwide cohort study to evaluate the dose-response relationship between alcohol consumption and kidney cancer risk by glycemic status (normoglycemia, prediabetes, and diabetes), adjusting for potential confounders. Over 9 million cancer-free participants who underwent the national health screening in Korea were followed for up to 10 years.

Materials and Methods

1. Data source and study population

The South Korean National Health Insurance Service (KNHIS) is a single-payer national health insurance system providing coverage for 97% of the South Korean population. The KNHIS also conducts biennial standardized national health screenings, with approximately 76% of the eligible population participating [23]. Data from the KNHIS were analyzed, comprising insurance claims data (including medical treatments, prescribed medications, and diagnoses coded using the International Classification of Diseases, 10th revision, clinical modification [ICD-10-CM]) and health examination data. The health examination data included laboratory test results, anthropometric measurements, and self-reported health-related behaviors.

The participant flowchart is shown in Fig. 1. Initially, 10,585,844 individuals aged 20 years or older who underwent national health screening between January 1, 2009, and December 31, 2009, were included in the study. Participants with a prior cancer diagnosis (n=162,512) were excluded. To minimize the potential for reverse causality and early detection bias, participants who were diagnosed with cancer or died within the first year following cohort enrollment were excluded from the analysis (n=93,862). Additionally, individuals missing data on variables of interest were excluded (n=837,139). Ultimately, 9,492,331 participants were followed until kidney cancer diagnosis, death, or December 31, 2018, whichever occurred first.

2. Definition of alcohol consumption

Alcohol consumption data were collected through self-administered standardized questionnaires during the national health screening. Participants provided self-reported data on alcohol consumption frequency, which was categorized into the following groups: 0, 1-2, 3-4, or 5-7 days per week. The amount of alcohol consumed per occasion was reported in terms of the number of glasses, with one glass of alcoholic beverage containing approximately 12 g of ethanol. The average daily alcohol consumption was calculated based on weekly consumption frequency and the amount consumed per occasion. Participants were classified into three groups based on their average daily alcohol consumption: non-drinkers, light-to-moderate drinkers (< 30 g/day for men; < 20 g/day for women), and heavy drinkers (≥ 30 g/day for men; ≥ 20 g/day for women) [24].

3. Definition of glycemic status

Fasting plasma glucose (FPG) levels were measured for each participant as part of the national health screening program. After an overnight fast, blood samples were collected by certified healthcare professionals at KNHIS-approved hospitals, adhering to quality control measures. Glycemic status was determined according to the American Diabetes Association criteria [25]. Normoglycemia was defined as an FPG level of < 100 mg/dL, prediabetes as an FPG level of 100-125 mg/dL, and diabetes as an FPG level of ≥ 126 mg/dL or the use of oral or injectable antidiabetic medications, with at least one insurance claim per year under ICD-10-CM codes E11–E14.

4. Definition of incident kidney cancer

The primary outcome of this study was the incidence of newly diagnosed kidney cancer cases recorded between January 2009 and December 2018. These diagnoses were based on the ICD-10-CM code (C64) during hospitalization, along with a cancer reimbursement code (V193). Physicians and medical institutions are required to use the V193 reimbursement code when certifying cancer diagnoses to facilitate a reduced co-payment rate of 5% for all cancer-related treatments and examinations. The National Cancer Registry is responsible for recording all patients with a confirmed cancer diagnosis using this V code.

5. Definition of the clinical variables

Anthropometric data, including height, weight, and waist circumference, were collected during the national health screening. Body mass index (BMI) was determined by dividing the participant’s weight (kg) by the square of their height (m²). According to Korean standards, obesity is defined as a BMI ≥ 25 kg/m². Blood pressure measurements, including systolic and diastolic values, were taken in a seated position after a 5-minute rest. Serum levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and creatinine were assessed. The estimated glomerular filtration rate (eGFR) was determined using the creatinine-based Modification of Diet in Renal Disease equation. CKD was defined as an eGFR of < 60 mL/min/1.73 m².

Dyslipidemia was defined as either a total serum cholesterol level > 240 mg/dL or the presence of an ICD-10-CM code (E78) accompanied by lipid-lowering medication prescriptions. Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or the presence of ICD-10-CM codes (I10-I13, I15) with antihypertensive medication prescriptions. The low-income group included participants who paid the lowest quartile of insurance fees or received free medical care.

Information on health-related behaviors was collected through a self-administered standardized questionnaire as part of the national health screening program. Smoking status was categorized as never a smoker (fewer than 100 cigarettes smoked in their lifetime), former smoker, or current smoker. Regular physical activity was defined as engaging in at least 20 minutes of vigorous-intensity physical activity three times per week or 30 minutes of moderate-intensity physical activity five times per week.

6. Statistical analysis

The incidence rate of kidney cancer was calculated per 100,000 person-years, stratified by alcohol consumption levels and glycemic status. The relationship between alcohol consumption and kidney cancer risk based on glycemic status was analyzed in a dose-response manner using hazard ratios (HRs) and 95% confidence intervals (CIs) obtained from multivariable Cox proportional hazards regression models. Model 1 was unadjusted, while model 2 adjusted for age and sex. Model 3 included adjustments for age, sex, smoking status, physical activity level, and income level. Model 4 was further adjusted for BMI, hypertension, dyslipidemia, and CKD. Stratified analysis was used to assess potential modification effects by covariates, such as age, sex, smoking status, physical activity level, income level, hypertension, dyslipidemia, CKD, and obesity status. The multiplicative interaction between alcohol and glycemic status was examined using the likelihood ratio test. All statistical tests were two-sided, and statistical significance was defined as p < 0.05. All analyses were conducted using SAS software ver. 9.3 (SAS Institute Inc.).

Results

1. Baseline characteristics

Over 78.1 million person-years of follow-up (mean duration, 8.2±0.9 years), a total of 12,381 individuals were newly diagnosed with kidney cancer. Table 1 presents the participants’ baseline characteristics. Patients diagnosed with kidney cancer were older and exhibited higher FPG levels and BMI (all p < 0.01). Additionally, they were more likely to be men, heavy drinkers, current smokers, and to have diabetes, dyslipidemia, hypertension, and CKD (all p < 0.01).

2. Dose-response association between alcohol consumption and kidney cancer risk according to glycemic status

Table 2 illustrates the dose-response association between alcohol consumption and kidney cancer risk by glycemic status. Among individuals with normoglycemia, light-to-moderate alcohol consumption was associated with a 6% reduced risk of kidney cancer (model 4: HR, 0.94; 95% CI, 0.89 to 0.99).

Individuals with diabetes who consumed light-to-moderate or heavy amounts of alcohol had an increased risk of kidney cancer in a dose-dependent manner compared to non-drinkers with normoglycemia (model 4: HR, 1.12; 95% CI, 1.03 to 1.22 and HR, 1.24; 95% CI, 1.09 to 1.42, respectively) (p for trend < 0.01).

S1 Table shows that consuming 3-4 glasses of alcohol on a single occasion or consuming alcohol 3-4 times per week was associated with a reduced risk of kidney cancer in those with normoglycemia (model 4: HR, 0.88; 95% CI, 0.81 to 0.95 and HR, 0.92; 95% CI, 0.84 to 0.997, respectively) but not in individuals with prediabetes or diabetes. Individuals with prediabetes or diabetes who consumed ≥ 8 glasses of alcohol on a single occasion had an increased risk of kidney cancer (model 4: HR, 1.11; 95% CI, 1.01 to 1.22 and HR, 1.31; 95% CI, 1.16 to 1.48, respectively).

3. Subgroup analysis of the dose-response association between alcohol consumption and kidney cancer risk by glycemic status

Table 3 presents the subgroup analysis of the dose-response association between alcohol consumption and kidney cancer risk by glycemic status. No significant differences were observed between the subgroups based on sex, smoking status, physical activity, income level, dyslipidemia, or CKD (all p for interaction > 0.05). The association between alcohol consumption and kidney cancer risk in relation to diabetes status differed by age, hypertension, and obesity (p for interaction < 0.001, < 0.001, and 0.002, respectively).

Discussion

In this large-scale nationwide cohort study, a modest U-shaped dose-response relationship between alcohol consumption and kidney cancer risk was observed exclusively among individuals with normoglycemia, after adjusting for potential confounding factors. Among individuals with prediabetes, no significant association was observed between alcohol consumption and kidney cancer risk. A dose-response association was observed in individuals with diabetes, with higher alcohol consumption levels corresponding to an increased risk of kidney cancer.

Despite the carcinogenic effects of alcohol, several previous studies have reported an inverse association between alcohol consumption and kidney cancer risk [5-11]. A cohort study conducted in the United States reported that, compared with alcohol consumption of > 0 to < 5 g per day, the multivariate relative risk (95% CI) for 15 to < 30 g per day and ≥ 30 g per day was 0.75 (0.63-0.90) and 0.71 (0.59-0.85), respectively [6]. Similarly, a pooled analysis of 12 cohort studies found that, compared with nondrinking, alcohol consumption of ≥ 15 g/day was associated with a decreased risk of kidney cancer (pooled multivariable relative risk, 0.72; 95% CI, 0.60 to 0.80) [5]. In contrast, another cohort study, which included U.S. residents, reported no significant association between alcohol consumption and kidney cancer risk [13]. Prior cohort studies were small-scale [8-11] or did not account for important confounders, such as diabetes or CKD [5-11]. Moreover, prior case–control studies were limited by survivorship, selection, and recall biases [18,19]. Notably, despite a possible interaction between alcohol consumption and hyperglycemia, whether the dose-response relationship between alcohol consumption and kidney cancer risk differs by glycemic status has not been investigated.

We provide new evidence that the association between alcohol consumption and kidney cancer risk varies based on the glycemic status of the individual. Healthcare providers should tailor patient education concerning alcohol consumption and kidney cancer risk, especially given the global rise in both alcohol consumption and diabetes prevalence.

The mechanisms underlying the differing dose-response effects of alcohol consumption on kidney cancer risk by glycemic status remain uncertain. However, we propose the following explanations. First, the mechanisms underlying these associations may involve the modulation of insulin signaling pathways by alcohol, which has been shown to affect cellular metabolism in ways that differ between normoglycemic and diabetic individuals. Light-to-moderate alcohol consumption may enhance insulin sensitivity in individuals with normoglycemia, potentially lowering their risk of kidney cancer [14,15]. Conversely, diabetes and prediabetes, conditions associated with insulin resistance and hyperinsulinemia, might attenuate the effect of alcohol on insulin sensitivity, thereby increasing kidney cancer risk. Second, the anti-inflammatory effects of light-to-moderate alcohol consumption may contribute to the decreased cancer risk observed in individuals with normoglycemia [26]. However, this effect may be absent in individuals with prediabetes or diabetes, who experience chronic inflammation and metabolic changes [27]. Finally, the diuretic effect of alcohol consumption might reduce kidney cancer risk by decreasing the contact time between carcinogens and renal epithelial cells. This is supported by studies demonstrating that coffee and tea consumption reduces kidney cancer risk [28]. However, the diuretic effects of alcohol might differ in individuals with hyperglycemia due to altered urine filtration [29].

Our study possesses several strengths. First, this large-scale nationwide cohort study utilized data from over 9 million individuals with up to 10 years of follow-up. The KNHIS database provides an accurate record of clinical progression of the cohort after enrollment. This allowed for a robust comparison of the dose-response relationship between alcohol consumption and kidney cancer risk across different glycemic statuses, resulting in reliable risk estimates for kidney cancer. Second, longitudinal data on lifestyle factors, blood test results, anthropometric measurements, and extensive medical records were collected. Alcohol consumption was assessed in more than 9 million participants using standardized questionnaires, minimizing the potential for recall bias. Third, to ensure high diagnostic accuracy, we identified kidney cancer cases using both the ICD-10-CM diagnostic code (C64) during hospitalization and the national registration code (V193). Fourth, our analyses were adjusted for potential confounding variables, including BMI, hypertension, smoking status, and CKD.

However, our study has some limitations. First, alcohol consumption was self-reported, which may introduce underreporting or misclassification, although such data are generally considered reliable [30]. Second, we lacked information on the type of alcohol consumed. Third, family history of kidney cancer was not included in our dataset. Fourth, we did not have access to pathological subtype data for kidney cancers; however, approximately > 90% of kidney cancers are renal cell carcinoma [3].

In conclusion, this nationwide cohort study demonstrated a modest U-shaped dose-response relationship between alcohol consumption and kidney cancer risk, which was observed exclusively in individuals with normoglycemia. Conversely, individuals with diabetes exhibited a dose-dependent increase in kidney cancer risk with alcohol consumption. These findings highlight the need for tailored patient education and personalized risk assessments concerning alcohol consumption and kidney cancer risk to address the growing burden of this disease. Given the increasing prevalence of both alcohol consumption and diabetes, healthcare professionals should incorporate these findings into preventive strategies aimed at reducing kidney cancer risk in at-risk populations. Additional studies are needed to elucidate the mechanisms by which alcohol consumption and hyperglycemia interact in the process of kidney carcinogenesis.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

crt-2024-996_S1_Table.pdf

NOTES

Ethical Statement

The study protocol received approval from the Institutional Review Board of Samsung Medical Center, Seoul, Korea (approval number SMC2019-08-106). The requirement for written informed consent was waived due to the use of anonymized data from the KNHIS. All study procedures adhered to the principles outlined in the Declaration of Helsinki.

Author Contributions

Conceived and designed the analysis: Park JH, Hong JY, She JJ, Park SH.

Collected the data: Han K.

Contributed data or analysis tools: Park JH, Hong JY, Han K.

Performed the analysis: Han K.

Wrote the paper: Park JH, Hong JY.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Funding

This research was supported by a Korea University Grant and also funded by the Basic Science Research Program through the National Research Foundation of Korea (NRF) under the Ministry of Education, Republic of Korea (2022R1I1A1A01054327) and the Bio & Medical Technology Development Program of the NRF under the Korean government (MSIT) (No. RS-2023-00222838). The funders played no role in the study’s design, conduct, or reporting.

Fig. 1.

Selection flowchart of the study population. Alcohol consumption status: none, light-to-moderate (< 30 g/day for men; < 20 g/day for women), and heavy (≥ 30 g/day for men; ≥ 20 g/day for women).

Table 1.

Participants baseline characteristics

Characteristic	Kidney cancer		p-value
Characteristic	No (n=9,479,950)	Yes (n=12,381)	p-value
Age (yr)	47.1±14.0	55.6±12.6	< 0.001
Male sex	5,195,920 (54.8)	8,834 (71.4)	< 0.001
Laboratory findings
Fasting glucose (mg/dL)	97.3±23.9	102.4±27.4	< 0.001
Total cholesterol (mg/dL)	195.5±41.5	197.2±37.7	< 0.001
HDL-cholesterol (mg/dL)	56.6±33.4	53.8±30.8	< 0.001
LDL-cholesterol (mg/dL)	113.6±38.9	114.6±39.0	0.002
eGFR (mL/min/1.73 m²)	87.6±43.5	83.5±48.2	< 0.001
Anthropometrics
Body mass index (kg/m²)	23.7±3.5	24.8±3.1	< 0.001
Waist circumference (cm)	80.3±9.4	84.7±8.5	< 0.001
Systolic BP (mmHg)	122.5±15.1	127.7±15.6	< 0.001
Diastolic BP (mmHg)	76.4±10.1	79.0±10.4	< 0.001
Alcohol consumption^a)
None	4,701,500 (49.6)	6,100 (49.3)	< 0.001
Light-to-moderate	3,996,326 (42.2)	4,956 (40.0)
Heavy	782,124 (8.3)	1,325 (10.7)
Frequency of alcohol consumption (day/wk)
0	4,701,500 (49.6)	6,100 (49.3)	< 0.001
1-2	3,478,988 (36.7)	4,054 (32.7)
3-4	932,871 (9.8)	1,446 (11.7)
≥ 5	366,591 (3.9)	781 (6.3)
Amount of alcohol consumed on a single occasion (glass/occasion)
0	4,701,500 (49.6)	6,100 (49.3)	< 0.001
1-2	696,922 (7.4)	822 (6.6)
3-4	1,040,159 (11.0)	1,339 (10.8)
5-7	1,603,820 (16.9)	2,246 (18.1)
≥ 8	1,437,549 (15.2)	1,874 (15.1)
Smoking status
Never	5,673,844 (59.9)	6,192 (50.0)	< 0.001
Former	1,312,993 (13.9)	2,569 (20.8)
Current	2,493,113 (26.3)	3,620 (29.2)
Regular exercise	1,714,290 (18.1)	2,789 (22.5)	< 0.001
Low-income status	1,667,818 (17.6)	1,937 (15.6)	< 0.001
Comorbidities
Diabetes	822,180 (8.7)	1,985 (16.0)	< 0.001
Hypertension	2,446,291 (25.8)	5,913 (47.8)	< 0.001
Dyslipidemia	1,726,761 (18.2)	3,297 (26.6)	< 0.001
Chronic kidney disease	646,246 (6.8)	1,433 (11.6)	< 0.001

Values are presented as mean±SD or number (%). BP, blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD, standard deviation.

Table 2.

Dose-response association between alcohol consumption and kidney cancer risk according to glycemic status

Glycemic status	Alcohol consumption^a)	No.	Event, n	Person-years	IR^b)	Hazard ratio (95% CI)
Glycemic status	Alcohol consumption^a)	No.	Event, n	Person-years	IR^b)	Model 1	Model 2	Model 3	Model 4
Normoglycemia	None	3,256,629	3,552	26,877,443	1.3	1 (reference)	1 (reference)	1 (reference)	1 (reference)
	Light-to-moderate	2,783,619	2,838	23,069,757	1.2	0.93 (0.89-0.98)	0.98 (0.93-1.04)	0.96 (0.91-1.01)	0.94 (0.89-0.99)
	Heavy	465,382	634	3,833,524	1.7	1.25 (1.15-1.36)	1.08 (0.99-1.18)	1.04 (0.95-1.13)	1.00 (0.91-1.09)

Prediabetes	None	991,314	1,521	8,124,904	1.9	1.42 (1.34-1.51)	1.11 (1.05-1.18)	1.11 (1.05-1.18)	1.05 (0.99-1.12)
	Light-to-moderate	937,966	1,406	7,722,418	1.8	1.38 (1.30-1.47)	1.08 (1.02-1.16)	1.05 (0.99-1.12)	0.99 (0.92-1.05)
	Heavy	233,256	445	1,908,525	2.3	1.77 (1.60-1.95)	1.24 (1.13-1.38)	1.20 (1.08-1.32)	1.10 (0.99-1.22)

Diabetes	None	459,657	1,027	3,655,723	2.8	2.13 (1.99-2.29)	1.28 (1.19-1.37)	1.28 (1.19-1.37)	1.10 (1.02-1.18)
	Light-to-moderate	279,697	712	2,257,007	3.2	2.39 (2.21-2.59)	1.34 (1.24-1.46)	1.30 (1.20-1.42)	1.12 (1.03-1.22)
	Heavy	84,811	246	677,333	3.6	2.76 (2.43-3.14)	1.52 (1.33-1.73)	1.46 (1.28-1.66)	1.24 (1.09-1.42)

Model 1: unadjusted; Model 2: adjusted for age and sex; Model 3: adjusted for age, sex, smoking status, physical activity, and income status; Model 4: adjusted for age, sex, smoking status, physical activity, income status, hypertension, dyslipidemia, chronic kidney disease, and body mass index. CI, confidence interval; IR, incidence rate.

^b) Kidney cancer incidence rate per 10,000 person-years.

Table 3.

Subgroup analysis of the dose-response association between alcohol consumption and kidney cancer risk according to glycemic status

Subgroup	Hazard ratio (95% CI)						p for interaction
	No diabetes			Diabetes
	No alcohol consumption^a)	Light-to-moderate alcohol consumption	Heavy alcohol consumption	No alcohol consumption^a)	Light-to-moderate alcohol consumption	Heavy alcohol consumption
Sex
Men	1 (reference)	0.97 (0.92-1.02)	1.05 (0.97-1.13)	1.07 (0.98-1.17)	1.09 (1.001-1.19)	1.21 (1.06-1.39)	0.946
Women	1 (reference)	0.85 (0.76-0.94)	0.83 (0.54-1.28)	1.14 (1.02-1.26)	1.14 (0.85-1.54)	1.48 (0.48-4.61)
Age (yr)
< 60	1 (reference)	0.95 (0.90-1.01)	1.06 (0.97-1.16)	1.14 (1.01-1.28)	1.09 (0.97-1.22)	1.25 (1.06-1.47)	< 0.001
≥ 60	1 (reference)	0.96 (0.89-1.03)	0.96 (0.84-1.08)	1.06 (0.97-1.15)	1.00 (0.89-1.13)	1.00 (0.81-1.24)
Current smoking
No	1 (reference)	0.93 (0.88-0.98)	1.00 (0.91-1.11)	1.07 (0.995-1.16)	1.09 (0.99-1.21)	1.25 (1.05-1.50)	0.376
Yes	1 (reference)	1.01 (0.92-1.10)	1.09 (0.98-1.22)	1.19 (1.01-1.41)	1.12 (0.97-1.29)	1.19 (0.98-1.45)
Regular physical activity
No	1 (reference)	0.96 (0.91-1.01)	1.07 (0.98-1.16)	1.05 (0.97-1.13)	1.11 (1.004-1.22)	1.26 (1.08-1.46)	0.305
Yes	1 (reference)	0.90 (0.82-0.99)	0.87 (0.75-1.01)	1.10 (0.95-1.26)	1.04 (0.89-1.22)	1.06 (0.81-1.38)
Low income
No	1 (reference)	0.94 (0.89-0.99)	1.00 (0.93-1.08)	1.08 (0.997-1.16)	1.10 (1.01-1.21)	1.24 (1.07-1.42)	0.852
Yes	1 (reference)	0.96 (0.85-1.08)	1.15 (0.95-1.38)	1.10 (0.93-1.29)	1.09 (0.89-1.34)	1.13 (0.79-1.60)
Hypertension
No	1 (reference)	0.95 (0.89-1.01)	1.09 (0.99-1.20)	1.20 (1.06-1.35)	1.17 (1.02-1.34)	1.57 (1.26-1.95)	< 0.001
Yes	1 (reference)	0.95 (0.89-1.02)	0.93 (0.84-1.04)	1.05 (0.96-1.14)	1.04 (0.94-1.15)	1.04 (0.88-1.23)
Dyslipidemia
No	1 (reference)	0.96 (0.91-1.01)	1.04 (0.96-1.13)	1.01 (0.92-1.11)	1.07 (0.96-1.18)	1.24 (1.05-1.46)	0.247
Yes	1 (reference)	0.90 (0.81-0.99)	0.94 (0.81-1.10)	1.18 (1.06-1.31)	1.12 (0.98-1.28)	1.14 (0.92-1.41)
Chronic kidney disease
No	1 (reference)	0.96 (0.92-1.01)	1.05 (0.97-1.13)	1.11 (1.03-1.20)	1.13 (1.04-1.23)	1.29 (1.12-1.48)	0.282
Yes	1 (reference)	0.82 (0.71-0.94)	0.84 (0.66-1.08)	0.93 (0.80-1.09)	0.90 (0.72-1.12)	0.74 (0.46-1.18)
Obesity
No	1 (reference)	0.96 (0.90-1.02)	1.03 (0.93-1.13)	1.14 (1.03-1.26)	1.19 (1.06-1.34)	1.16 (0.94-1.42)	0.002
Yes	1 (reference)	0.92 (0.86-0.99)	0.97 (0.88-1.08)	0.97 (0.88-1.07)	0.97 (0.86-1.09)	1.18 (0.99-1.40)

CI, confidence interval.

^a) Alcohol consumption was classified according to the average daily amount of alcohol consumed as follows: none, light-to-moderate (< 30 g/day for men; < 20 g/day for women), and heavy (≥ 30 g/day for men; ≥ 20 g/day for women). Hazard ratios and 95% CIs were adjusted for age, sex, smoking status, physical activity, income status, hypertension, dyslipidemia, chronic kidney disease, and body mass index.

REFERENCES

1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49. Article PubMed
2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. Article PubMed
3. Young M, Jackson-Spence F, Beltran L, Day E, Suarez C, Bex A, et al. Renal cell carcinoma. Lancet. 2024;404:476–91. Article PubMed
4. Rumgay H, Shield K, Charvat H, Ferrari P, Sornpaisarn B, Obot I, et al. Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. Lancet Oncol. 2021;22:1071–80. Article PubMed PMC
5. Lee JE, Hunter DJ, Spiegelman D, Adami HO, Albanes D, Bernstein L, et al. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. J Natl Cancer Inst. 2007;99:801–10. Article PubMed
6. Lew JQ, Chow WH, Hollenbeck AR, Schatzkin A, Park Y. Alcohol consumption and risk of renal cell cancer: the NIH-AARP diet and health study. Br J Cancer. 2011;104:537–41. Article PubMed PMC PDF
7. Allen NE, Balkwill A, Beral V, Green J, Reeves G; Million Women Study Collaborators. Fluid intake and incidence of renal cell carcinoma in UK women. Br J Cancer. 2011;104:1487–92. Article PubMed PMC PDF
8. Karami S, Daugherty SE, Purdue MP. A prospective study of alcohol consumption and renal cell carcinoma risk. Int J Cancer. 2015;137:238–42. Article PubMed PMC PDF
9. Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol. 2007;166:932–40. Article PubMed
10. Wozniak MB, Brennan P, Brenner DR, Overvad K, Olsen A, Tjonneland A, et al. Alcohol consumption and the risk of renal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 2015;137:1953–66. PubMed
11. Nicodemus KK, Sweeney C, Folsom AR. Evaluation of dietary, medical and lifestyle risk factors for incident kidney cancer in postmenopausal women. Int J Cancer. 2004;108:115–21. Article PubMed
12. Minami T, Inoue M, Sawada N, Yamaji T, Iwasaki M, Tsugane S. Alcohol consumption, tobacco smoking, and subsequent risk of renal cell carcinoma: the JPHC study. Cancer Sci. 2021;112:5068–77. Article PubMed PMC PDF
13. Macleod LC, Hotaling JM, Wright JL, Davenport MT, Gore JL, Harper J, et al. Risk factors for renal cell carcinoma in the VITAL study. J Urol. 2013;190:1657–61. Article PubMed PMC
14. Bonnet F, Disse E, Laville M, Mari A, Hojlund K, Anderwald CH, et al. Moderate alcohol consumption is associated with improved insulin sensitivity, reduced basal insulin secretion rate and lower fasting glucagon concentration in healthy women. Diabetologia. 2012;55:3228–37. Article PubMed PDF
15. Booyse FM, Pan W, Grenett HE, Parks DA, Darley-Usmar VM, Bradley KM, et al. Mechanism by which alcohol and wine polyphenols affect coronary heart disease risk. Ann Epidemiol. 2007;17(5 Suppl):S24–31. Article PubMed
16. Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K. The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Front Immunol. 2020;11:1582.Article PubMed PMC
17. Pereira CS, Molz P, Palazzo RP, de Freitas TA, Maluf SW, Horta JA, et al. DNA damage and cytotoxicity in adult subjects with prediabetes. Mutat Res. 2013;753:76–81. Article PubMed
18. Greving JP, Lee JE, Wolk A, Lukkien C, Lindblad P, Bergstrom A. Alcoholic beverages and risk of renal cell cancer. Br J Cancer. 2007;97:429–33. Article PubMed PMC PDF
19. Pelucchi C, Galeone C, Montella M, Polesel J, Crispo A, Talamini R, et al. Alcohol consumption and renal cell cancer risk in two Italian case-control studies. Ann Oncol. 2008;19:1003–8. Article PubMed
20. Manthey J, Shield KD, Rylett M, Hasan OS, Probst C, Rehm J. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet. 2019;393:2493–502. Article PubMed
21. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2022 [Internet]. Centers for Disease Control and Prevention; 2022 [cited 2023 Apr 25]. Available from: https://www.cdc.gov/diabetes/php/data-research/index.html
22. Bae JH, Han KD, Ko SH, Yang YS, Choi JH, Choi KM, et al. Diabetes fact sheet in Korea 2021. Diabetes Metab J. 2022;46:417–26. Article PubMed PMC PDF
23. Lee YH, Han K, Ko SH, Ko KS, Lee KU; Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Data analytic process of a nationwide population-based study using national health information database established by National Health Insurance Service. Diabetes Metab J. 2016;40:79–82. Article PubMed PMC PDF
24. Park JH, Han K, Hong JY, Park YS, Park JO. Association between alcohol consumption and pancreatic cancer risk differs by glycaemic status: a nationwide cohort study. Eur J Cancer. 2022;163:119–27. Article PubMed
25. Rossi SH, Klatte T, Usher-Smith J, Stewart GD. Epidemiology and screening for renal cancer. World J Urol. 2018;36:1341–53. Article PubMed PMC PDF
26. Imhof A, Woodward M, Doering A, Helbecque N, Loewel H, Amouyel P, et al. Overall alcohol intake, beer, wine, and systemic markers of inflammation in western Europe: results from three MONICA samples (Augsburg, Glasgow, Lille). Eur Heart J. 2004;25:2092–100. Article PubMed
27. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S14–31. Article PubMed PDF
28. Rhee J, Lim RK, Purdue MP. Coffee consumption and risk of renal cancer: a meta-analysis of cohort evidence. Cancer Causes Control. 2022;33:101–8. Article PubMed PMC PDF
29. Wasada T, Kuroki H, Arii H, Maruyama A, Katsumori K, Aoki K, et al. Hyperglycemia facilitates urinary excretion of C-peptide by increasing glomerular filtration rate in non-insulin-dependent diabetes mellitus. Metabolism. 1995;44:1194–8. Article PubMed
30. Giovannucci E, Colditz G, Stampfer MJ, Rimm EB, Litin L, Sampson L, et al. The assessment of alcohol consumption by a simple self-administered questionnaire. Am J Epidemiol. 1991;133:810–7. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Dose-Response Association between Alcohol Consumption and Kidney Cancer Risk Differs According to Glycemic Status: A Nationwide Cohort Study of 9.4 Million Individuals

Cancer Res Treat. 2025;57(4):1178-1186. Published online January 31, 2025

DOI: https://doi.org/10.4143/crt.2024.996

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Association between Obesity and Melanoma Risk in an Asian Population: A Nationwide Cohort Study

Dose-Response Association between Alcohol Consumption and Kidney Cancer Risk Differs According to Glycemic Status: A Nationwide Cohort Study of 9.4 Million Individuals

Fig. 1. Selection flowchart of the study population. Alcohol consumption status: none, light-to-moderate (< 30 g/day for men; < 20 g/day for women), and heavy (≥ 30 g/day for men; ≥ 20 g/day for women).

Fig. 1.

Dose-Response Association between Alcohol Consumption and Kidney Cancer Risk Differs According to Glycemic Status: A Nationwide Cohort Study of 9.4 Million Individuals

Characteristic	Kidney cancer		p-value
Characteristic	No (n=9,479,950)	Yes (n=12,381)	p-value
Age (yr)	47.1±14.0	55.6±12.6	< 0.001
Male sex	5,195,920 (54.8)	8,834 (71.4)	< 0.001
Laboratory findings
Fasting glucose (mg/dL)	97.3±23.9	102.4±27.4	< 0.001
Total cholesterol (mg/dL)	195.5±41.5	197.2±37.7	< 0.001
HDL-cholesterol (mg/dL)	56.6±33.4	53.8±30.8	< 0.001
LDL-cholesterol (mg/dL)	113.6±38.9	114.6±39.0	0.002
eGFR (mL/min/1.73 m²)	87.6±43.5	83.5±48.2	< 0.001
Anthropometrics
Body mass index (kg/m²)	23.7±3.5	24.8±3.1	< 0.001
Waist circumference (cm)	80.3±9.4	84.7±8.5	< 0.001
Systolic BP (mmHg)	122.5±15.1	127.7±15.6	< 0.001
Diastolic BP (mmHg)	76.4±10.1	79.0±10.4	< 0.001
Alcohol consumption^a)
None	4,701,500 (49.6)	6,100 (49.3)	< 0.001
Light-to-moderate	3,996,326 (42.2)	4,956 (40.0)
Heavy	782,124 (8.3)	1,325 (10.7)
Frequency of alcohol consumption (day/wk)
0	4,701,500 (49.6)	6,100 (49.3)	< 0.001
1-2	3,478,988 (36.7)	4,054 (32.7)
3-4	932,871 (9.8)	1,446 (11.7)
≥ 5	366,591 (3.9)	781 (6.3)
Amount of alcohol consumed on a single occasion (glass/occasion)
0	4,701,500 (49.6)	6,100 (49.3)	< 0.001
1-2	696,922 (7.4)	822 (6.6)
3-4	1,040,159 (11.0)	1,339 (10.8)
5-7	1,603,820 (16.9)	2,246 (18.1)
≥ 8	1,437,549 (15.2)	1,874 (15.1)
Smoking status
Never	5,673,844 (59.9)	6,192 (50.0)	< 0.001
Former	1,312,993 (13.9)	2,569 (20.8)
Current	2,493,113 (26.3)	3,620 (29.2)
Regular exercise	1,714,290 (18.1)	2,789 (22.5)	< 0.001
Low-income status	1,667,818 (17.6)	1,937 (15.6)	< 0.001
Comorbidities
Diabetes	822,180 (8.7)	1,985 (16.0)	< 0.001
Hypertension	2,446,291 (25.8)	5,913 (47.8)	< 0.001
Dyslipidemia	1,726,761 (18.2)	3,297 (26.6)	< 0.001
Chronic kidney disease	646,246 (6.8)	1,433 (11.6)	< 0.001

Glycemic status	Alcohol consumption^a)	No.	Event, n	Person-years	IR^b)	Hazard ratio (95% CI)
Glycemic status	Alcohol consumption^a)	No.	Event, n	Person-years	IR^b)	Model 1	Model 2	Model 3	Model 4
Normoglycemia	None	3,256,629	3,552	26,877,443	1.3	1 (reference)	1 (reference)	1 (reference)	1 (reference)
	Light-to-moderate	2,783,619	2,838	23,069,757	1.2	0.93 (0.89-0.98)	0.98 (0.93-1.04)	0.96 (0.91-1.01)	0.94 (0.89-0.99)
	Heavy	465,382	634	3,833,524	1.7	1.25 (1.15-1.36)	1.08 (0.99-1.18)	1.04 (0.95-1.13)	1.00 (0.91-1.09)

Prediabetes	None	991,314	1,521	8,124,904	1.9	1.42 (1.34-1.51)	1.11 (1.05-1.18)	1.11 (1.05-1.18)	1.05 (0.99-1.12)
	Light-to-moderate	937,966	1,406	7,722,418	1.8	1.38 (1.30-1.47)	1.08 (1.02-1.16)	1.05 (0.99-1.12)	0.99 (0.92-1.05)
	Heavy	233,256	445	1,908,525	2.3	1.77 (1.60-1.95)	1.24 (1.13-1.38)	1.20 (1.08-1.32)	1.10 (0.99-1.22)

Diabetes	None	459,657	1,027	3,655,723	2.8	2.13 (1.99-2.29)	1.28 (1.19-1.37)	1.28 (1.19-1.37)	1.10 (1.02-1.18)
	Light-to-moderate	279,697	712	2,257,007	3.2	2.39 (2.21-2.59)	1.34 (1.24-1.46)	1.30 (1.20-1.42)	1.12 (1.03-1.22)
	Heavy	84,811	246	677,333	3.6	2.76 (2.43-3.14)	1.52 (1.33-1.73)	1.46 (1.28-1.66)	1.24 (1.09-1.42)

Subgroup	Hazard ratio (95% CI)						p for interaction
	No diabetes			Diabetes
	No alcohol consumption^a)	Light-to-moderate alcohol consumption	Heavy alcohol consumption	No alcohol consumption^a)	Light-to-moderate alcohol consumption	Heavy alcohol consumption
Sex
Men	1 (reference)	0.97 (0.92-1.02)	1.05 (0.97-1.13)	1.07 (0.98-1.17)	1.09 (1.001-1.19)	1.21 (1.06-1.39)	0.946
Women	1 (reference)	0.85 (0.76-0.94)	0.83 (0.54-1.28)	1.14 (1.02-1.26)	1.14 (0.85-1.54)	1.48 (0.48-4.61)
Age (yr)
< 60	1 (reference)	0.95 (0.90-1.01)	1.06 (0.97-1.16)	1.14 (1.01-1.28)	1.09 (0.97-1.22)	1.25 (1.06-1.47)	< 0.001
≥ 60	1 (reference)	0.96 (0.89-1.03)	0.96 (0.84-1.08)	1.06 (0.97-1.15)	1.00 (0.89-1.13)	1.00 (0.81-1.24)
Current smoking
No	1 (reference)	0.93 (0.88-0.98)	1.00 (0.91-1.11)	1.07 (0.995-1.16)	1.09 (0.99-1.21)	1.25 (1.05-1.50)	0.376
Yes	1 (reference)	1.01 (0.92-1.10)	1.09 (0.98-1.22)	1.19 (1.01-1.41)	1.12 (0.97-1.29)	1.19 (0.98-1.45)
Regular physical activity
No	1 (reference)	0.96 (0.91-1.01)	1.07 (0.98-1.16)	1.05 (0.97-1.13)	1.11 (1.004-1.22)	1.26 (1.08-1.46)	0.305
Yes	1 (reference)	0.90 (0.82-0.99)	0.87 (0.75-1.01)	1.10 (0.95-1.26)	1.04 (0.89-1.22)	1.06 (0.81-1.38)
Low income
No	1 (reference)	0.94 (0.89-0.99)	1.00 (0.93-1.08)	1.08 (0.997-1.16)	1.10 (1.01-1.21)	1.24 (1.07-1.42)	0.852
Yes	1 (reference)	0.96 (0.85-1.08)	1.15 (0.95-1.38)	1.10 (0.93-1.29)	1.09 (0.89-1.34)	1.13 (0.79-1.60)
Hypertension
No	1 (reference)	0.95 (0.89-1.01)	1.09 (0.99-1.20)	1.20 (1.06-1.35)	1.17 (1.02-1.34)	1.57 (1.26-1.95)	< 0.001
Yes	1 (reference)	0.95 (0.89-1.02)	0.93 (0.84-1.04)	1.05 (0.96-1.14)	1.04 (0.94-1.15)	1.04 (0.88-1.23)
Dyslipidemia
No	1 (reference)	0.96 (0.91-1.01)	1.04 (0.96-1.13)	1.01 (0.92-1.11)	1.07 (0.96-1.18)	1.24 (1.05-1.46)	0.247
Yes	1 (reference)	0.90 (0.81-0.99)	0.94 (0.81-1.10)	1.18 (1.06-1.31)	1.12 (0.98-1.28)	1.14 (0.92-1.41)
Chronic kidney disease
No	1 (reference)	0.96 (0.92-1.01)	1.05 (0.97-1.13)	1.11 (1.03-1.20)	1.13 (1.04-1.23)	1.29 (1.12-1.48)	0.282
Yes	1 (reference)	0.82 (0.71-0.94)	0.84 (0.66-1.08)	0.93 (0.80-1.09)	0.90 (0.72-1.12)	0.74 (0.46-1.18)
Obesity
No	1 (reference)	0.96 (0.90-1.02)	1.03 (0.93-1.13)	1.14 (1.03-1.26)	1.19 (1.06-1.34)	1.16 (0.94-1.42)	0.002
Yes	1 (reference)	0.92 (0.86-0.99)	0.97 (0.88-1.08)	0.97 (0.88-1.07)	0.97 (0.86-1.09)	1.18 (0.99-1.40)

Table 1. Participants baseline characteristics

Values are presented as mean±SD or number (%). BP, blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD, standard deviation.

Table 2. Dose-response association between alcohol consumption and kidney cancer risk according to glycemic status

Kidney cancer incidence rate per 10,000 person-years.

Table 3. Subgroup analysis of the dose-response association between alcohol consumption and kidney cancer risk according to glycemic status

CI, confidence interval.

Alcohol consumption was classified according to the average daily amount of alcohol consumed as follows: none, light-to-moderate (< 30 g/day for men; < 20 g/day for women), and heavy (≥ 30 g/day for men; ≥ 20 g/day for women). Hazard ratios and 95% CIs were adjusted for age, sex, smoking status, physical activity, income status, hypertension, dyslipidemia, chronic kidney disease, and body mass index.